Antigen News and Research RSS Feed - Antigen News and Research

VolitionRx initiates study to assess NuQ blood tests for detection of prostate cancer

VolitionRx initiates study to assess NuQ blood tests for detection of prostate cancer

VolitionRx Limited today announced that it has initiated a study to assess the feasibility of using the Company’s NuQ blood tests to detect prostate cancer. The study is in collaboration with the Surrey Cancer Research Institute of the University of Surrey in the UK. [More]
New biosensor test system developed for accurate measurements of protein molecule concentration in blood

New biosensor test system developed for accurate measurements of protein molecule concentration in blood

Researchers from the General Physics Institute of the Russian Academy of Sciences and Moscow Institute of Physics and Technology have developed a new biosensor test system based on magnetic nanoparticles. [More]
Immunological changes during pregnancy may influence response to influenza vaccination

Immunological changes during pregnancy may influence response to influenza vaccination

In a study to be presented on Feb. 5 in an oral concurrent session at 1:15 p.m. EST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting, in Atlanta, researchers will present findings from a study titled, T-follicular helper (Thf) cell expansion varies by trimester after influenza vaccination in pregnancy. [More]
Study provides new insights into breast cancer metastasis

Study provides new insights into breast cancer metastasis

It has long been thought that cancer metastasizes, or spreads, when a single cancer cell escapes from the original tumor, travels through the bloodstream and sets up shop in distant organs. However, a growing body of evidence suggests that these bad actors don't travel alone; instead they migrate through the body in cellular clusters, like gangs. [More]
MabVax receives FDA authorization to initiate 89Zr-HuMab-5B1 Phase I trial in pancreatic cancer patients

MabVax receives FDA authorization to initiate 89Zr-HuMab-5B1 Phase I trial in pancreatic cancer patients

MabVax Therapeutics Holdings, Inc., a clinical-stage oncology drug-development company, announces receipt of notice from the U.S. Food and Drug Administration authorizing initiation of a Phase I clinical trial with 89Zr-HuMab-5B1 as a new generation PET scan cancer imaging agent in patients with pancreatic cancer. [More]
A more effective method for detecting metastatic prostate cancer

A more effective method for detecting metastatic prostate cancer

Conventional imaging methods have limited sensitivity for detecting metastatic prostate cancer. With appropriate, timely treatment vital to survival and quality of life, better imaging has been an ongoing goal. [More]
UAB discovery may offer new therapeutic approaches to asthma

UAB discovery may offer new therapeutic approaches to asthma

University of Alabama at Birmingham researchers have found a previously unknown step in the pathway that leads to asthma, a discovery that may offer new therapeutic approaches to this incurable disease. Asthma affects more than 25 million people in the United States, including about 7 million children. [More]
Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Astellas US LLC, a United States (U.S.) subsidiary of Tokyo-based Astellas Pharma Inc., and Medivation, Inc. today announced that results from the STRIVE trial of enzalutamide compared to bicalutamide in men with castration-resistant prostate cancer (CRPC) were published in the Journal of Clinical Oncology. [More]
Monitoring HBcrAg levels could help optimise PEG-IFN therapy

Monitoring HBcrAg levels could help optimise PEG-IFN therapy

Serum hepatitis B core-related antigen could serve as a quantitative marker of response to pegylated interferon therapy in patients with chronic hepatitis B virus infection positive for hepatitis B e antigen (HBeAg), findings indicate. [More]
STAT4 variant predicts HBV IFNα response

STAT4 variant predicts HBV IFNα response

Variation in the STAT4 gene is associated with response to interferon (IFN)α therapy in patients with hepatitis B e antigen-positive chronic hepatitis B virus infection, suggests research published in Hepatology. [More]
Shire announces resubmission of lifitegrast NDA to FDA for treatment of dry eye disease in adults

Shire announces resubmission of lifitegrast NDA to FDA for treatment of dry eye disease in adults

Shire plc today announced it has resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration for its investigational candidate, lifitegrast, for the treatment of signs and symptoms of dry eye disease in adults. Shire resubmitted the NDA in response to the complete response letter (CRL) the company received from the FDA on October 16, 2015. [More]
Immunotherapy could be the future of cancer treatments

Immunotherapy could be the future of cancer treatments

For decades most cancers have been treated with the standard of care treatments which typically include surgery, radiation and/or chemotherapy. Now there is talk that immunotherapy represents "the future of cancer treatments." [More]
Fc Receptor Protein Collection

Fc Receptor Protein Collection

AMSBIO announces an extensive collection of recombinant Fc receptor proteins, including their common variants, to help accelerate the development of therapeutic monoclonal antibodies (mAb). [More]
CSU's BioMARC awarded DoD contract to help develop new vaccines to combat encephalitic viruses

CSU's BioMARC awarded DoD contract to help develop new vaccines to combat encephalitic viruses

Colorado State University's Biopharmaceutical Manufacturing and Academic Resource Center has been awarded a 10-month, $4.6 million contract funded by the Department of Defense to help develop and manufacture new vaccines to fight encephalitic viruses that cause inflammation of the brain. [More]
Animal antibodies help identify diseased cells during immunohistology procedures

Animal antibodies help identify diseased cells during immunohistology procedures

We all know it from biology lessons at school: Antibodies help us to ward off disease and are essential components of our immune system. What many people do not know is that physicians and scientists use animal antibodies to identify diseased or mutated cells. [More]
New technique may accelerate development of novel vaccines

New technique may accelerate development of novel vaccines

An interdisciplinary team of Oxford University researchers has devised a new technique to speed up the development of novel vaccines. [More]
TG4010 vaccine promising in advanced NSCLC

TG4010 vaccine promising in advanced NSCLC

Addition of the TG4010 vaccine to first-line chemotherapy improves outcomes in patients with advanced non-small-cell lung cancer, show the results of a placebo controlled trial. [More]
Scientists find new way to re-engineer body’s immune system to target cancer

Scientists find new way to re-engineer body’s immune system to target cancer

Scientists have demonstrated a new way of re-engineering the body’s immune system to target cancer, paving the way for a new generation of drugs, unprecedented in safety and effectiveness. [More]
UM SOM to team up with industry to develop vaccine for preventing deadly bacterial infections

UM SOM to team up with industry to develop vaccine for preventing deadly bacterial infections

The Center for Vaccine Development at the University of Maryland School of Medicine will participate in a partnership with industry to develop a vaccine to prevent a group of deadly bacterial infections that occur commonly among hospital patients. [More]

Docetaxel remains effective in prostate cancer even after treatment with androgen-deprivation therapy

A study presented at the 2016 Genitourinary Cancers Symposium shows that 40 percent of patients with castration-resistant metastatic prostate cancer (mCRPC) treated with docetaxel following abiraterone had at least 50 percent reduction in prostate specific antigen (PSA), demonstrating the activity of this drug sequencing. [More]
Advertisement